Loading clinical trials...
Loading clinical trials...
Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months
Conditions
Interventions
telbivudine
Locations
1
South Korea
Department of Internal Medicine, Yonsei University College of Medicine
Seoul, South Korea
Start Date
June 1, 2010
Primary Completion Date
May 1, 2012
Completion Date
May 1, 2012
Last Updated
February 2, 2012
NCT06671093
NCT06885710
NCT06263959
NCT06295328
NCT02883647
NCT04139850
Lead Sponsor
Yonsei University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions